Featured Press Releases

Fresenius-Kabi_17122024

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies

Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies

  • 18 Apr 2024

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to...

Vensica Medical raises $11M to advance Phase 2 trials for its overactive bladder treatment

Vensica Medical raises $11M to advance Phase 2 trials for its overactive bladder treatment

New Study Suggests 5-MTHF as Effective Alternative to Folic Acid in Later Pregnancy

New Study Suggests 5-MTHF as Effective Alternative to Folic Acid in Later Pregnancy

Biohack skin longevity with Futurecode Booster

Biohack skin longevity with Futurecode Booster

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

VectorY Therapeutics Raises €74.5 Million to Advance Neurodegenerative Disease Pipeline

VectorY Therapeutics Raises €74.5 Million to Advance Neurodegenerative Disease Pipeline

  • VectorY Therapeutics
  • 11 Nov 2026
ProBio Signs Exclusive Global Licensing Agreement with AbTis for Next-Generation ADC Development

ProBio Signs Exclusive Global Licensing Agreement with AbTis for Next-Generation ADC Development

  • ProBio Inc.
  • 10 Nov 2026
Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

  • Waters Corporation
  • 10 Nov 2026
Bayer’s SUNHARBO® (asundexian) Receives FDA Approval for Stroke Risk Reduction

Bayer’s SUNHARBO® (asundexian) Receives FDA Approval for Stroke Risk Reduction

  • Bayer
  • 10 Nov 2026
Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

  • Tenpoint Therapeutics, Ltd.
  • 09 Nov 2026
BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

  • UCB
  • 09 Nov 2026

Most Popular
November   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.